WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

Disclosures for additional planners can be found here.

Faculty

Ann Marie Navar, MD, PhD

Associate Professor
Departments of Internal Medicine and Population and Data Sciences
Member
Division of Cardiology
UT Southwestern Medical Center
Dallas, Texas, United States

Disclosures

Ann Marie Navar, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: AstraZeneca Pharmaceuticals LP; Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; Cerner; Janssen; Lilly; New Amsterdam Pharma; Novartis; Novo Nordisk; Pfizer, Inc.
Research funding from: Amgen, Inc.; Bristol Myers Squibb Company; Esperion Therapeutics, Inc.; Janssen

Kausik K. Ray, MBChB, MD, MPhil, FRCP

President
European Atherosclerosis Society
Professor of Public Health and Honorary Consultant Cardiologist
Director
Imperial Centre for Cardiovascular Disease Prevention
Deputy Director
Imperial Clinical Trials Unit
Head of Commercial Trials
Imperial College London
London, United Kingdom

Disclosures

Kausik K. Ray, MBChB, MD, MPhil, FRCP, has the following relevant financial relationships:
Consultant or advisor for: Abbott; Amgen, Inc.; AstraZeneca Pharmaceuticals LP; Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; Cargene; CRISPR; Daiichi Sankyo, Inc.; Esperion Therapeutics, Inc.; Kowa Company Ltd.; Lilly; New Amsterdam Pharma; Novartis; Novo Nordisk; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Resverlogix Corp; Sanofi; SCRIBE; Silence Therapeutics; Vaxxinity; Viatris
Speaker or member of speakers bureau for: Amgen, Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Novartis; Novo Nordisk; Sanofi; Viatris
Research funding from: Amgen, Inc.; Daiichi Sankyo, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi
Stock options from: Cargene; Pemi 31

Editor

Anne M. Sendaydiego, PharmD

Medical Education Director, WebMD Global, LLC

Disclosures

Anne M. Sendaydiego, PharmD, has no relevant financial relationships.

Compliance Reviewer

Yaisanet Oyola, MD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Yaisanet Oyola, MD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

From Medscape Education

Challenging the Harmful Myths About ASCVD Management: The Experts Set the Record Straight

Authors: Ann Marie Navar, MD, PhD; Kausik K. Ray, MBChB, MD, MPhil, FRCPFaculty and Disclosures

processing....

Posted: 03/21/2023

This educational activity is intended for an international audience of non-US cardiologists, primary care physicians, endocrinologists/diabetologists, nephrologists, and nurses.

The goal of this activity is for learners to be better able to understand common myths or misinterpretations of evidence around atherosclerotic cardiovascular disease (ASCVD) management in order to improve overall patient care.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Common misunderstandings that relate to ASCVD risk and lipid management
Have greater competence related to
- The management of patients at increased ASCVD risk, including those with dyslipidemia

Educational Impact Challenge

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 7

Download Slides

Activity Transcript

Print
Like Tweet

Activity Transcript

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Ann Marie Navar, MD, PhD

Kausik K. Ray, MBChB, MD, MPhil, FRCP

Editor

Anne M. Sendaydiego, PharmD

Compliance Reviewer

Yaisanet Oyola, MD

Peer Reviewer

Challenging the Harmful Myths About ASCVD Management: The Experts Set the Record Straight

Educational Impact Challenge